Global ACE Inhibitors Market Overview
As per MRFR analysis, the ACE Inhibitors Market Size was estimated at 5.55 (USD Billion) in 2024. The ACE Inhibitors Market Industry is expected to grow from 5.74 (USD Billion) in 2025 to 7.76 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 3.40% during the forecast period (2025 - 2034). Growing geriatric population, rising awareness and screening programmes, combination therapies, rising prevalence of cardiovascular diseases, are the key market drivers enhancing the market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
ACE Inhibitors Market Trends
- Elderly population growth, increased awareness, and screening programmes is driving the market growth
ACE (Angiotensin-Converting Enzyme) inhibitors is rapidly expanding and in high demand. The rising incidence of cardiovascular illnesses globally is a major contributor. Major health issues include hypertension, heart failure, and diabetic nephropathy, and ACE inhibitors are frequently recommended to treat these conditions. The need for ACE inhibitors is growing along with the number of people being diagnosed with these cardiovascular illnesses. The increasing older population worldwide is another significant cause. The usage of drugs like Angiotensin Converting Enzyme is necessary because aged people are more vulnerable to cardiovascular illnesses and their associated problems. The need for these treatments has increased in tandem with the growing elderly population. Furthermore, public awareness of cardiovascular illnesses and the value of early detection have grown significantly. There are now more screening programmes available to find those at risk for hypertension and other cardiovascular diseases. As a result, more patients are receiving ACE inhibitors as part of their treatment after being identified as having these disorders. Favourable reimbursement policies and increasing awareness both significantly contribute to market growth. Reimbursement policies have been implemented in numerous nations to lower costs and increase patient access to important cardiovascular drugs like ACE inhibitors. Increased utilisation and market demand result from this.
Another factor influencing the market for Angiotensin Converting Enzyme is the use of combination therapy. To effectively treat cardiovascular disorders, ACE inhibitors are usually used in conjunction with other drugs like beta-blockers or diuretics. Since ACE inhibitors are a crucial component of many treatment plans, the adoption of combination therapy increases the market for these drugs. It is important to note that technological developments in pharmaceutical formulations, including sustained-release formulations and alternate administration modalities, have also fueled market expansion. The demand for ACE inhibitors is increased as a result of these developments, which improve patient compliance and convenience. Thus, driving the ACE Inhibitors market revenue.
ACE Inhibitors Market Segment Insights
ACE Inhibitors Drug Insights
The ACE Inhibitors market segmentation, based on Drug includes Lisinopril, Ramipril, Enalapril, Benazepril, Fosinopril, Captopril, Moexipril and others. The lisinopril segment dominated the market, accounting for 33.31% of market revenue. The factors including an increase in the use of lisinopril to improve survival after a heart attack and an increase in the demand for lisinopril medications to treat high blood pressure.
ACE Inhibitors Application Insights
The ACE Inhibitors market segmentation, based on Application, includes Heart Failure, Hypertension, Diabetes, Heart Attack, Chronic Kidney Disease and others. The heart failure category generated the most income (36.45%). The factors such as the rise in the research and development activities for developing advanced drugs for the treatment of heart failure and the growing demand for Lisinopril for improving survival after a heart attack.
ACE Inhibitors Dosage Form Insights
The ACE Inhibitors market segmentation, based on Dosage Form includes Oral Tablets and Oral Solution. The oral tablets segment dominated the market, accounting for 61.42% of market revenue. This is due to the segment provide a number of benefits, such as simplicity in administration, precision in dosing, and stability. Typically, oral tablets are designed to deliver sustained release of the drug, delivering a reliable and long-lasting therapeutic impact.
ACE Inhibitors Distribution Channel Insights
The ACE Inhibitors market segmentation, based on Drug includes Retail Pharmacy, Hospital Pharmacy, E-commerce Websites and Online Drug Stores. The retail pharmacy segment dominated the market, accounting for 51.22% of market revenue. Retail pharmacies are frequently chosen by people looking for ACE inhibitors because they provide convenience, simple access to prescriptions, and the chance to speak with pharmacists.
ACE Inhibitors Regional Insights
By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North America ACE Inhibitors Market dominated this market in 2022 (45.80%). The high frequency of cardiovascular disorders, the sizeable older population, and the region's well-established healthcare infrastructure all contribute to the market's growth. Further, the U.S. ACE Inhibitors market held the largest market share, and the Canada Armor Materials market was the fastest growing market in the North America region.
Further, the major countries studied in the market report are The U.S., Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: ACE INHIBITORS MARKET SHARE BY REGION 2022 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe ACE Inhibitors market accounts for the second-largest market share. The market is expanding as a result of favourable reimbursement policies, rising older population, and increased awareness of cardiovascular health. Further, the German ACE Inhibitors market held the largest market share, and the UK ACE Inhibitors market was the fastest growing market in the European region
The Asia-Pacific ACE Inhibitors Market is expected to grow at the fastest CAGR from 2023 to 2034. This development is being fueled by a sizable population base, rising urbanisation, shifting lifestyles, and an increase in cardiovascular disease prevalence. Moreover, China’s ACE Inhibitors market held the largest market share, and the Indian ACE Inhibitors market was the fastest growing market in the Asia-Pacific region.
ACE Inhibitors Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the ACE Inhibitors market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, ACE Inhibitors industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the ACE Inhibitors industry to benefit clients and increase the market sector. In recent years, the ACE Inhibitors industry has offered some of the most significant advantages to medicine. Major players in the Angiotensin Converting Enzyme (ACE) Market, including Pfizer Inc., AstraZeneca Pharmaceutical Company, Novartis AG, Johnson and Johnson Services, United Therapeutics Corporation, Merck KGaA, Teva Pharmaceutical Industry, Sandoz AG, Novartis AG, Bayer AG , Sanofi and others, are attempting to increase market demand by investing in research and development operations.
Pfizer Inc, a renowned pharmaceutical company, is actively involved in the ACE Inhibitors Market. The main medical conditions that ACE inhibitors are used to treat include heart failure and hypertension (high blood pressure). Pfizer is well-known in the cardiovascular treatment industry and provides a number of ACE inhibitor medications."Lisinopril," one of Pfizer's most important ACE inhibitors, is frequently used for the treatment of hypertension and heart failure. Angiotensin-converting enzyme (ACE) inhibition, decreased angiotensin II synthesis, and vasodilation are how lisinopril exerts its action. To accommodate the varying demands of patients, it is offered in a range of strengths and forms.Angiotensin Converting Enzyme (ACE) Market participation by Pfizer goes beyond product development. The business invests in clinical trials and research to examine the effectiveness and safety of ACE inhibitors in various patient populations. Additionally, Pfizer promotes the judicious use of Angiotensin Converting Enzyme for the best patient outcomes through educational activities to increase knowledge of hypertension.
AstraZeneca, a leading pharmaceutical company, is actively involved in the ACE Inhibitors Market. A class of drugs known as ACE inhibitors is largely used to treat heart failure and hypertension (high blood pressure). AstraZeneca has a significant market share in the therapeutic field for the heart and offers a number of ACE inhibitor medications. One of the most important ACE inhibitors produced by AstraZeneca is "Ramipril," which is frequently given for the treatment of post-myocardial infarction (heart attack) symptoms, heart failure, and hypertension. Ramipril lowers blood pressure by blocking the angiotensin-converting enzyme (ACE), which causes vasodilation. To meet the various demands of patients, it is offered in different strengths and forms.Involvement of AstraZeneca in the ACE Inhibitors Market extends beyond product sales. The business actively invests in R&D to investigate new ACE inhibitor applications and treatment approaches. Additionally, they work along with organisations and medical professionals to promote cardiovascular health and the proper use of ACE inhibitors.
Key Companies in the ACE Inhibitors market include
ACE Inhibitors Industry Developments
2021:A new generation ACE inhibitor from Sanofi has been given regulatory approval due to its increased tolerability and effectiveness. With the approval, the business is now able to provide patients with heart failure and hypertension with a cutting-edge therapeutic choice.
2020:In order to increase access to their ACE inhibitor for patients without insurance or with inadequate insurance, Boehringer Ingelheim has launched a patient assistance programme. The programme strives to lower financial obstacles and make sure that patients get the prescription drugs they require.
ACE Inhibitors Market Segmentation
ACE Inhibitors Drug Outlook
-
Lisinopril
-
Ramipril
-
Enalapril
-
Benazepril
-
Fosinopril
-
Captopril
-
Moexipril
-
others
ACE Inhibitors Application Outlook
-
Heart Failure
-
Hypertension
-
Diabetes
-
Heart Attack
-
Chronic Kidney Disease
-
others
ACE Inhibitors Dosage Form Outlook
-
Oral Tablets
-
Oral Solution
ACE Inhibitors Distribution Channel Outlook
-
Retail Pharmacy
-
Hospital Pharmacy
-
E-commerce Websites
-
Online Drug Stores
ACE Inhibitors Regional Outlook
-
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Rest of Europe
-
Asia-Pacific
-
China
-
Japan
-
India
-
Australia
-
South Korea
-
Australia
-
Rest of Asia-Pacific
-
Rest of the World
-
Middle East
-
Africa
-
Latin America
| Report Attribute/Metric |
Details |
|
Market Size 2024
|
5.55 (USD Billion)
|
|
Market Size 2025
|
5.74 (USD Billion)
|
|
Market Size 2034
|
7.76 (USD Billion)
|
|
Compound Annual Growth Rate (CAGR)
|
3.40 % (2025 - 2034)
|
|
Report Coverage
|
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
|
|
Base Year
|
2024
|
|
Market Forecast Period
|
2025 - 2034
|
|
Historical Data
|
2020 - 2024
|
| Report Coverage |
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
Drug, Application, Dosage Form, Distribution Channel, and Region |
| Geographies Covered |
North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered |
The U.S., Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled |
Pfizer Inc.,AstraZeneca Pharmaceutical Company,Novartis AG,Johnson and Johnson Services,United Therapeutics Corporation, Merck KGaA, Teva Pharmaceutical Industry, Sandoz AG,Novartis AG, Bayer AG , Sanofi |
| Key Market Opportunities |
Cardiovascular diseases are becoming more prevalent, and managing hypertension is becoming more common |
| Key Market Dynamics |
Increasing Cardiovascular Disease Incidence |
ACE Inhibitors Market Highlights:
Frequently Asked Questions (FAQ) :
The ACE Inhibitors market size was valued at USD 5.2 Billion in 2022.
The market is projected to grow at a CAGR of 3.40% during the forecast period, 2034.
North America had the largest share in the market
The key players in the market are Pfizer Inc.,AstraZeneca Pharmaceutical Company,Novartis AG,Johnson and Johnson Services,United Therapeutics Corporation, Merck KGaA, Teva Pharmaceutical Industry, Sandoz AG,Novartis AG, Bayer AG , Sanofi.
The Lisinopril category dominated the market in 2022.
The Heart Failure had the largest share in the market.
